Video
Dr. Abida on next steps with PARP inhibitors in prostate cancer
Author(s):
Video Player is loading.
Wassim Abida, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses what the next steps should be with PARP inhibitors in prostate cancer. The PARP inhibitors olaparib (Lynparza) and rucaparib (Rubraca) are approved by the FDA for the treatment of patients with metastatic castration-resistant prostate cancer, and other PARP agents are moving through the pipeline.
Related Videos
Study data point to gender disparities in oncology research citations
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
Rana McKay, MD, on the role of radium-223 in the modern era
Related Content
